
03/27/2025
NOW is the time to support adolescent patients with non-invasive, non-pharmacological TMS technology to improve care. The FDA cleared Magstim TMS for treatment of U.S. adolescent patients aged 15-21 for MDD. Practices using Magstim Horizon 3.0 and Inspire can begin treating adolescents immediately, following standard patient care protocols.*
Fact: Major depression impacts more than 5 million U.S. adolescents every year, and NIH data shows that 20% of those aged 12 to 16 have had at least one major depressive episode.*
Magstim is now the only TMS system which can treat MDD, Anxious Depression, OCD, and Adolescent Depression with a single treatment coil.
To learn more, visit www.magstim.com.
*Horizon 3.0 TMS Therapy Systems are indicated as an adjunct for the treatment of MDD in adolescent patients (age 15-21)
*NIH Source: https://lnkd.in/gejk5K2X